Skip to main content
Clinical Trials/ACTRN12615001053516
ACTRN12615001053516
Completed
未知

A Randomised Controlled Trial in older adults with mild cognitive or memory impairment, investigating the Cognitive Benefits of a Combined Flavonoid/Fatty Acid Intervention and Underlying Mechanisms of Action: The COGNITIVE AGING NUTRITION and NEUROGENESIS (CANN) Trial

Swinburne Univeristy0 sites240 target enrollmentOctober 7, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
Mild Cognitive Impairment
Sponsor
Swinburne Univeristy
Enrollment
240
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 7, 2015
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Swinburne Univeristy

Eligibility Criteria

Inclusion Criteria

  • For main study:
  • Male and female, aged 55 years and over
  • Mild cognitive impairment (MCI) or subjective memory impairment (SMI) with no indication of clinical dementia or depression
  • Willing and able to provide written informed consent.
  • Understands and is willing and able to comply with all study procedures.
  • Fluent in written and spoken English.
  • In good general health including blood biochemical, haematological and urinalysis within the normal range at
  • screening (as judged by the clinical advisor)
  • Normal, or corrected to normal vision and hearing
  • Right handed, for MRI

Exclusion Criteria

  • Diagnosis of Alzheimer's disease (AD) or other form of dementia or significant neurological disorder
  • Parent or sibling who developed premature dementia \<60y (suggestive of a familial monogenic form of cognitive decline)
  • Past history or MRI evidence of brain damage including significant trauma, stroke, learning difficulties or serious neurological disorder, including loss of consciousness \> 24 hours
  • History of alcohol or drug dependency within the last 2 years
  • Other clinically diagnosed psychiatric disorder likely to affect the cognitive measures (as judged by clinical adviser)
  • Existing diagnosed gastrointestinal disorders likely to impact on absorption of flavonoids and fatty acids (as judged by clinical adviser)
  • Major cardiovascular event, e.g. myocardial infarction or stroke, in the last 12 months
  • Carotid stents or severe stenosis
  • Known allergy to fish or any other component in the intervention supplements
  • Existing medical conditions likely to affect the study measures (as judged by clinical adviser)

Outcomes

Primary Outcomes

Not specified

Similar Trials